- Report
- April 2024
- 160 Pages
From €5764EUR$5,999USD£4,956GBP
- Report
- February 2024
- 180 Pages
Global
From €5284EUR$5,499USD£4,543GBP
- Report
- February 2022
- 113 Pages
Global
From €4324EUR$4,500USD£3,718GBP
- Report
- September 2022
- 141 Pages
Global
From €3430EUR$3,570USD£2,950GBP
- Book
- April 2024
- 1280 Pages
- Book
- November 2011
- 496 Pages
Global
- Book
- October 2011
- 280 Pages
- Book
- October 2010
- 200 Pages
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects the motor neurons in the brain and spinal cord. It is characterized by muscle weakness, difficulty speaking, and difficulty swallowing. As the disease progresses, it can lead to paralysis and eventually death. Treatment options are limited and there is no cure.
The ALS market is a subset of the larger neurology market. It is a growing market, driven by increasing awareness of the disease and the development of new treatments. There is a need for more effective treatments and therapies to improve the quality of life for those living with ALS.
Companies in the ALS market include Biogen, Novartis, Sanofi, and Teva Pharmaceuticals. These companies are developing treatments and therapies to improve the lives of those living with ALS. Show Less Read more